AIM News and Press, AIM ImmunoTech Inc. From 04/10/24

OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent ovarian cancer may have a ...

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) --  AI-Media, the global leader in AI-powered captioning, is set to unveil two new products at the prestigious NAB Show 2024, scheduled from 14-17 April in Las Vegas USA. Renowned for its cutting-edge innovations serving the broadcast industry, AI-Me...

LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- AI-Media, a global leader in end-to-end captioning technology solutions, is excited to announce its newly established partnership with DAZN, the global sports entertainment streaming platform. Through this collaboration, AI-Media will deliver live and re...

2024-04-02 11:52:52 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips AIM ImmunoTech (NYSEMKT: AIM ) just reported results for the fourth quarter of 2023. AIM ImmunoTech reported earnings per share of -26 cents. This was below the analyst es...

2024-04-02 11:32:08 ET AIM ImmunoTech Inc. (AIM) Q4 2023 Earnings Conference Call April 2, 2024, 8:30 AM ET Company Participants Thomas Equels - Chief Executive Officer Dr. Christopher McAleer - Scientific Officer Conference Call Participants James Molloy...

2024-04-02 07:34:16 ET More on AIM ImmunoTech AIM stock dips amid mixed results for post-COVID fatigue therapy Seeking Alpha’s Quant Rating on AIM ImmunoTech Historical earnings data for AIM ImmunoTech Financial information for AIM ImmunoTech ...

Year marked by growing body of promising data demonstrating Ampligen’s potential to address multiple high-value indications Company to host conference call and webcast today, April 2 nd at 8:30 AM ET OCALA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- AIM Immuno...

2024-04-01 13:48:59 ET More on AIM ImmunoTech AIM stock dips amid mixed results for post-COVID fatigue therapy Seeking Alpha’s Quant Rating on AIM ImmunoTech Historical earnings data for AIM ImmunoTech Financial information for AIM ImmunoTech ...

OCALA, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM ImmunoTech, will present at the MedInvest Biotech & Phar...

OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q4/FY2023 operational and financial...